Frontiers in Pharmacology | Pharmacoepidemiology

Original Research

Published on 16 May 2025

Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database

in Pharmacoepidemiology

Bingqing Wang
Kaidi Zhao
Ningyi Xian
Landong Ren
Jiashu Liu
Chen Tu
Dewu Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1497708

3,678 views
1 citation

Original Research

Published on 14 May 2025

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database

in Pharmacoepidemiology

Yuan-Yuan Wu
Qiong-Lian Huang
Zhan-Yang Luo
Xiao-Yun Song
You-Yang Shi
Jin-Zhou Zheng
Sheng Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1529342

3,617 views
3 citations

Original Research

Published on 13 May 2025

Time-dependent impact of immunosuppressant regimens on cardiovascular outcomes in kidney transplant recipients: a nationwide cohort study

in Pharmacoepidemiology

Jinhyun Park
Wonhui Choi
Jinseub Hwang
Young-Mi Ah
Byung Ha Chung
Yun-Kyoung Song

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1540576

2,066 views

Original Research

Published on 12 May 2025

Drug stockpiling behavior and its impact on anxiety among the general public in the early stage after the lifting of China’s Zero-COVID policy: results from a web-based survey

in Pharmacoepidemiology

Yu Huang
Shuiyang Xu
Xiang Zhao
Lei Wang
Qiaohong Lv
Suxian Wu
Qingqing Wu
Xuehai Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524068

1,558 views
1 citation

Original Research

Published on 09 May 2025

Construction and validation of a meropenem-induced liver injury risk prediction model: a multicenter case-control study

in Pharmacoepidemiology

Yan He
Hongqin Ke
Jianyong Zhu
Xin Yuan
Hongliang Li
Wenwen Wu
Shuman Yang
Huibin Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1542554

2,572 views

Original Research

Published on 06 May 2025

Impact of polypharmacy phenogroups on different heart failure phenotypes in patients with chronic heart failure: a retrospective examination of real-world cohort

in Pharmacoepidemiology

Aseel Sukik
Ahmed Tarek Aboughalia
Abdul Haseeb Said Wali
Amro Al Radaideh
Omar Mohamed Elsayed
Mohammed A. Amer
Joud Said Abuodeh
Oyelola A. Adegboye
AbdelNaser Elzouki
Mohammed Ibn-Mas‘ud Danjuma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1526112

2,620 views

Original Research

Published on 06 May 2025

Adherence and persistence with istradefylline treatment in patients with Parkinson’s disease in the United States

in Pharmacoepidemiology

Reversa Joseph
Joyce Qian
Hannah Cummings
Yen-Hua Chen
Shubham Tewari
Michael Soileau

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1548631

3,156 views

Original Research

Published on 02 May 2025

An in-depth exploration of the association between olanzapine, quetiapine and acute pancreatitis based on real-world datasets and network toxicology analysis

in Pharmacoepidemiology

Shuang Wang
Liying Song
Yuanjie Sun
Haonan Zhou
Jia Yao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1529416

5,445 views

Original Research

Published on 02 May 2025

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system

in Pharmacoepidemiology

Liangxia Li
Qianqian Xu
Liangfang Pang
Yarui Liu
Yuanyuan Lu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1519865

5,257 views
2 citations

Original Research

Published on 30 Apr 2025

Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system

in Pharmacoepidemiology

Hao Liu
Wei Yan
Jinsong Li
Dezhi Yan
Di Luo

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1483669

4,342 views
3 citations

Original Research

Published on 30 Apr 2025

Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study

in Pharmacoepidemiology

Xihui Yu
Jiahong Zhong
Xuemei Zhuang
Zhuomiao Lin
Hongbo Fu
Yaofeng Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533902

4,826 views

Original Research

Published on 28 Apr 2025

Prescribing characteristics and guideline concordance of antihypertensive western and Chinese patent medicine in Internet hospitals in China: a cross-sectional study

in Pharmacoepidemiology

Tiantian Zhou
Xing Liao
Jiaxin Zuo
Fang Han
Ruogu Meng
Lin Zhuo
Guozhen Liu
Jing Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1580787

2,972 views

Original Research

Published on 28 Apr 2025

Charting the COVID-19 vaccination journey in Saudi Arabia: Insights into post-vaccination adverse effects and immunization dynamics

in Pharmacoepidemiology

Gehad M. Subaiea
Nawaf Alkhateeb
Faisal Sahman
Abdulrahman Alsudayri
Abdulkarim M. Almudayni
Hamoud Alrashidi
Abdulrahman M Alshammari
Abdulwahab Alamri
Sultan Almuntashiri
Arshad Hussain

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1561410

1,887 views
1 citation

Original Research

Published on 28 Apr 2025

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases

in Pharmacoepidemiology

Tao Wang
Zhiwei Cui
Yingyong Ou
Siyu Lou
Huayou Chen
Chengyu Zhu
Linmei Zhou
Fan Zou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1530697

5,242 views
2 citations

Original Research

Published on 25 Apr 2025

Acute liver injury and diffuse subcutaneous pneumatosis following compound paracetamol and amantadine hydrochloride tablets poisoning: a case report

in Pharmacoepidemiology

Zhiwen Zhao
Bo Wang
Lanlan Cai
Xuefang Liu
Zhicheng Fang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1503449

17,929 views
1 citation

Systematic Review

Published on 25 Apr 2025

Evaluating the efficacy of valproic acid in alcohol use disorder: a systematic analysis of clinical trials from ClinicalTrials.gov

in Pharmacoepidemiology

Fahad S. Alshehri

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1503035

3,907 views

Original Research

Published on 24 Apr 2025

Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database

in Pharmacoepidemiology

Xiang Li
Shu Wen Wang
Zhi-Jie Zhang
Zhan Yang Luo
Jia Feng Tang
Tao Tao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1498191

3,496 views
1 citation

Original Research

Published on 16 Apr 2025

Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study

in Pharmacoepidemiology

Yu-Ching Li
Yu-Hsiang Kuan
Yih Yang
Shuo-Yan Gau
Kun-Yu Su
Tung-Han Tsai
Kuang-Hua Huang
Chien-Ying Lee

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1518545

2,282 views
2 citations

Original Research

Published on 16 Apr 2025

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database

in Pharmacoepidemiology

Yunlin Yang
Jinfeng Liu
Wei Wei

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510992

6,975 views
3 citations

Original Research

Published on 16 Apr 2025

Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology

in Pharmacoepidemiology

Hao Xie
Lin Jiang
Junya Peng
Haoyang Hu
Meifen Han
Bin Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1564127

4,958 views
1 citation

Editorial

Published on 15 Apr 2025

Editorial: Emerging trends in real-world pharmacoepidemiology: 2023

in Pharmacoepidemiology

Mohammed S. Salahudeen
Tatiane Da Silva Dal Pizzol
Li-Ting Kao
Gregory M. Peterson

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1601477

2,179 views

Correction

Published on 07 Apr 2025

Corrigendum: Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

in Pharmacoepidemiology

Fengqi Zhou
Haiou He
Jing Gao
Zhen Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1586073

1,091 views

Original Research

Published on 04 Apr 2025

Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia

in Pharmacoepidemiology

Gashaw Sisay Chanie
Wagaye Atalay
Tirsit Ketsela Zeleke
Zemenu Wube Bayleyegn
Yonas Sisay Aragie
Gizachew Kassahun Bizuneh
Mihret Melese
Rahel Belete Abebe

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1394458

2,327 views

Original Research

Published on 26 Mar 2025

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024

in Pharmacoepidemiology

Jiali Xia
Jing Zhang
Hongyu Zhu
Li Ding

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1565480

4,069 views
1 citation

571 articles

articles

Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database

Time-dependent impact of immunosuppressant regimens on cardiovascular outcomes in kidney transplant recipients: a nationwide cohort study

Drug stockpiling behavior and its impact on anxiety among the general public in the early stage after the lifting of China’s Zero-COVID policy: results from a web-based survey

Construction and validation of a meropenem-induced liver injury risk prediction model: a multicenter case-control study

Impact of polypharmacy phenogroups on different heart failure phenotypes in patients with chronic heart failure: a retrospective examination of real-world cohort

Adherence and persistence with istradefylline treatment in patients with Parkinson’s disease in the United States

An in-depth exploration of the association between olanzapine, quetiapine and acute pancreatitis based on real-world datasets and network toxicology analysis

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system

Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system

Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study

Prescribing characteristics and guideline concordance of antihypertensive western and Chinese patent medicine in Internet hospitals in China: a cross-sectional study

Charting the COVID-19 vaccination journey in Saudi Arabia: Insights into post-vaccination adverse effects and immunization dynamics

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases

Acute liver injury and diffuse subcutaneous pneumatosis following compound paracetamol and amantadine hydrochloride tablets poisoning: a case report

Evaluating the efficacy of valproic acid in alcohol use disorder: a systematic analysis of clinical trials from ClinicalTrials.gov

Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database

Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database

Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology

Editorial: Emerging trends in real-world pharmacoepidemiology: 2023

Corrigendum: Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024